Alpha-Lipoic Acid 400mg Cuts Insulin Resistance and Liver Enzymes in Overweight PCOS Women at 12 Weeks
For women with polycystic ovary syndrome (PCOS), alpha-lipoic acid (ALA) increasingly shows up as a molecule that cuts two chains at once. A randomized controlled trial published in Gynecological Endocrinology gave overweight/obese PCOS women ALA 400mg/day for 12 weeks. Result: peripheral tissue insulin sensitivity AND hepatic insulin clearance both improved with statistical significance. Liver enzymes ALT and AST simultaneously dropped, signaling reduced risk of non-alcoholic fatty liver disease (NAFLD) progression.
PCOS is a common endocrine condition with estimated 5–10% prevalence in Korean reproductive-age women. The molecular core circuit: insulin resistance → compensatory hyperinsulinemia → ovarian androgen excess → anovulation, acne, hirsutism, irregular cycles. At the same time, chronic hyperinsulinemia stimulates hepatic de novo lipogenesis, with NAFLD comorbidity reaching 30–40%. Both problems start from the same molecular circuit.
ALA is an endogenously synthesized sulfur-containing cofactor essential for the mitochondrial pyruvate dehydrogenase complex. As a supplement (R-ALA or racemic ALA), it works in layers:
- AMPK activation: same circuit as exercise and metformin. Insulin signal bypass + glucose uptake increase
- GLUT4 translocation: muscle glucose uptake increase → peripheral insulin sensitivity improvement
- Hepatic gluconeogenesis suppression: metformin-like effect
- Antioxidant + anti-inflammatory: glutathione regeneration, NF-κB attenuation. Reduced low-grade chronic inflammation
- Mitochondrial function recovery: partial restoration of impaired mitochondrial function in NAFLD
The 12-week RCT showed: HOMA-IR reduction, fasting insulin reduction, ALT and AST reductions, and in some patients reductions in androgen markers (testosterone, free androgen index). Some data suggest ALA + metformin combination outperforms metformin alone.
The INOSIDEX trial adds another angle. In 155 postmenopausal women with metabolic syndrome, inositol + ALA combination for 6 months produced over 20% HOMA-IR reduction in 67% of patients, insulin level reduction in 89%, and triglyceride reduction in 43%. The same circuit operates in postmenopausal women.
Dosing per clinical data falls in 200–600mg/day. Pre-meal fasting administration (30 minutes before food) achieves highest absorption (~30–40%); postprandial absorption drops below half. Recommended approach:
- PCOS insulin resistance: 400mg pre-meal, once daily. Reassess at 12–16 weeks
- With NAFLD: 600mg split (200mg breakfast + 200mg lunch + 200mg dinner) for 12–16 weeks
- With inositol: myo-inositol 2g + D-chiro-inositol 50mg + ALA 400mg
Side effects are generally well tolerated. GI discomfort, mild headache, rare urticaria. With diabetes medications (metformin, insulin), monitor for hypoglycemia. ALA may interfere with thyroid medication absorption — separate by 4 hours. Partial competition with biotin (vitamin H) absorption — long-term use should consider biotin co-supplementation. Pregnancy data are insufficient.
Dietary ALA-containing foods are limited. Trace amounts in spinach, broccoli, tomato, potato, liver, and yeast — but reaching clinical doses through food alone is impractical. Supplementation is essentially the only route.
For women with PCOS or NAFLD, the takeaway: if metformin is insufficient or poorly tolerated, ALA is a meaningful complement or alternative; both problems share the same insulin-resistance circuit, so a single supplement can untangle both chains; if no change appears at week 12, consider another approach (inositol combination, metformin add-on).